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Abstract:  Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder of 
skeletal malformations and progressive extraskeletal ossification. There is still no effective 
treatment for FOP. All FOP individuals harbor conserved point mutations in ACVR1 gene 
that are thought to cause ACVR1 constitutive activation and activate BMP signal   
pathway. The constitutively active ACVR1 is also found to be able to cause   
endothelial-to-mesenchymal transition (EndMT) in endothelial cells, which may cause the 
formation of FOP lesions. MicroRNAs (miRNAs) play an essential role in regulating cell 
differentiation. Here, we verified that miR-148a directly targeted the 3' UTR of ACVR1 
mRNA by reporter gene assays and mutational analysis at the miRNA binding sites, and 
inhibited ACVR1 both at the protein level and mRNA level. Further, we veriﬁed that   
miR-148a could inhibit the mRNA expression of the Inhibitor of DNA binding (Id) gene 
family thereby suppressing the BMP signaling pathway. This study suggests miR-148a is 
an important mediator of ACVR1, thus offering a new potential target for the development 
of therapeutic agents against FOP. 
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1. Introduction 
Fibrodysplasia ossificans progressiva (FOP) is a rare and catastrophic genetic disorder of 
progressive heterotopic ossification (HO). It is the most catastrophic disorder of HO in humans, 
causing immobility through progressive metamorphosis of skeletal muscle and soft connective tissue 
into a second skeleton of heterotopic bone [1]. A mutation (c.G617A, p.R206H) in the glycine-serine 
(GS) activation domain of activin receptor type I (ACVR1, also called activin-like kinase 2 (ALK2)) 
was found through a linkage and sequencing analysis, and was reported in all sporadic and familial 
cases of classic FOP [2–6]. ACVR1 belongs to the transforming growth factor (TGF)-β superfamily, 
and it is a bone morphogenetic protein (BMP) type I receptor. ACVR1 is normally inactive until it 
binds to extracellular BMP, stimulates its phosphorylation within the GS domain, activating ACVR1 
to recruit and phosphorylate Smad signaling molecules, including Smads 1, 5, and 8 within the cell; 
these subsequently form heteromeric complexes with the co-regulatory Smad (Smad4) and accumulate 
in the nucleus. Once phosphorylated, Smads then regulate target gene transcription by directly binding 
to DNA and interacting with different transcriptional co-activators or co-repressors [7]. The inhibitor 
of DNA binding (Id) genes are well-characterized BMP response genes in a variety of cell types and 
have broad effects on growth and differentiation [8–12]. There are four mammalian Id proteins (Id1–4) 
belonging to the helix-loop-helix (HLH) transcription factor family. The upregulated expression of 
Id1-3 in the differentiation of osteoblasts induced by BMPs, suggests a role for Id proteins in   
BMP-induced osteoblast lineage-specific differentiation [13]. The classic FOP-associated ACVR1 
mutation R206H renders ACVR1 constitutively active and increases the phosphorylation of 
downstream Smad1 effector proteins. The mutant ACVR1-R206H sensitizes mesenchymal cells to 
BMP-induced osteoblast differentiation, and stimulates new bone formation [14]. Interestingly, it is 
reported that the expression of constitutively active ACVR1 in endothelial cells could cause 
endothelial-to-mesenchymal transition (EndMT) and acquisition of a stem cell-like phenotype. These 
stem-like cells could be triggered to differentiate into osteoblasts, chondrocytes or adipocytes [15]. HO 
in FOP lesions begins with a mesenchymal condensation, followed by chondrogenesis and 
endochondral ossification. It is possible that FOP lesions could be derived from EndMT. 
As there is still no effective treatment for FOP, it is very urgent to find a useful therapeutic 
approach to inhibit BMP signaling or target ACVR1 directly.  
MicroRNAs (miRNAs) are small (~22 nucleotides long), single-stranded non-coding RNAs that 
mediate posttranscriptional silencing of target genes. In animals, miRNAs usually bind to 
complementary sites in the 3' untranslated region (UTR) of specific target genes and lead to the 
repression of protein expression or the promotion of target mRNA degradation [16]. miRNAs have 
emerged as key regulators of diverse biological processes, including cell growth and apoptosis [17], 
development [18], cancer [19], immune response [20] and so on. In addition, the pattern of miRNA 
expression in human multipotent mesenchymal stromal cells (MSC) is found to be distinct from that in 
pluripotent stem cells, and specific populations of miRNAs are regulated in MSC during Int. J. Mol. Sci. 2012, 13                 
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differentiation targeted toward specific cell types [18,21]. There is increasing evidence for miRNA 
involvement in osteogenic differentiation of human multipotent MSCs from bone marrow [22]. A 
recent study validated ACVR1 as a target of miR-30c which plays a critical role in human adipocyte 
differentiation [23]. miRNAs have been developed as novel and promising therapeutic strategies in 
many diseases, such as cancer [24,25], cardiovascular diseases [26,27] and viral diseases [28,29]. 
Several efficient miRNA delivery methods have been developed, which make miRNA-based 
therapeutic products develop rapidly in recent years [24,30,31].  
We initially conducted a survey of the potential miRNAs that could bind to ACVR1 mRNA using 
bioinformatics methods and miR-148a was identified as a strong candidate. MiR-148a belongs to   
miR-148 family (miR-148a, miR-148b and miR-152), which share high sequence indentity. MiR-148a 
is located at chromosome 7p15.2 and recent studies have found it could regulate cell proliferation [32] 
or promote apoptosis [33] in specific cell types. Moreover, some studies revealed that miR-148a could 
promote cell hypomethylation by targeting human DNMT3b [34] and DNMT1 [35], which proved to 
be important in aberrant CD4+ T cell DNA hypomethylation of lupus [35]. A recent study found that 
miR-148a expression is upregulated in dendritic cells (DCs) on maturation and activation induced by 
TLR agonists, which, in turn, inhibit the upregulation of MHC II expression, cytokine production, and 
antigen (Ag) presentation of DCs by targeting calcium/calmodulin-dependent protein kinase II 
(CaMKII). Therefore, miR-148a could act as negative regulator for the innate response and   
Ag-presenting capacity of DC [36]. Furthermore, miR-148a may play a role in metastasis related to 
hepatocellular carcinoma [37]. Interestingly, it was found that miR-148a was both underexpressed in 
MSCs that differentiate from human embryonic stem cells (ESs) (called ES-MSCs) compared with 
normal ESs [38], and in osteo-differentiated MSCs compared with normal MSCs [22]. We speculated 
that the negative correlation between the downregulation of miR-148a and upregulation of ACVR1 
may reveal a mechanism. In this study, we found miR-148a could negatively regulate ACVR1 directly 
by targeting the 3' UTR of ACVR1 mRNA. 
2. Results and Discussion 
2.1. Interaction Between miR-148a and ACVR1 3' UTR Binding Sites 
In initial studies, TargetScan 5.1 [39], miRanda [40] and miRDB [41] were used to identify 
miRNAs with putative binding sites in ACVR1 3' UTR. There were 33 miRNAs (miRNA list is shown 
in Supplementary Table S1) including miR-148a could be predicted by all the three programs. As  
miR-148a had been shown to be related with osteo-differentiation [22,38], we chose miR-148a for 
further study. The predicted interaction between miR-148a and its target sites in ACVR1 3' UTR is 
illustrated in Figure 1B. We found that the miR-148a binding sites were conserved in different 
vertebrates (Figure 1C). Int. J. Mol. Sci. 2012, 13                 
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Figure 1. Interaction of miR-148a with the 3' UTR of ACVR1 mRNA. (A) Schema of 
human ACVR1 mRNA and miR-148a binding site in its 3'-UTR sequence. (B) Schematic 
indication of miR-148a binding sites in the 3' UTR of ACVR1 mRNA based on 
TargetScan 5.1 prediction (seed sequences at 448–454 bp of ACVR1 3' UTR were 
highlighted in grey, mutant bases for vector pmir-ACVR1-3'UTR-mut construction were 
shown as lowercase letters). (C) Multiple sequence alignment of the miR-148a binding 
sites in different species. The alignment was performed with ClustalW. The miR-148a seed 
sequences at 448–454 bp of ACVR1 3' UTR were framed. * conservative site. (D) Luciferase 
reporter vector structure. The vector contained two expression units; one for the ﬁreﬂy 
luciferase gene (luc2) and the other for the Renilla luciferase gene (hRluc-neo fusion) 
expression. Luc2 unit was driven by a human phosphoglycerate kinase (PGK) promoter 
and contained multiple cloning sites (MCS) downstream of the luc2 sequence. ACVR1  
3' UTR containing a putative miRNA target region was cloned into the MCS. The Renilla 
luciferase unit was driven by an SV40 early promoter and used to adjust for variations in 
transfection efﬁciency among experiments and normalize fireﬂy luciferase activity. 
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To test whether miR-148a can alter the expression of ACVR1, we cloned a region of its 3' UTR 
containing the putative miRNA-binding sequences into a dual-luciferase miRNA target expression 
vector (pmirGLO vector). The structure of the luciferase reporter vector is illustrated in Figure 1D. We 
co-transfected pmirGLO-ACVR1-3'UTR and miR-148a mimic into HeLa cells. Negative control (NC) 
mimic and mock transfection were assayed at the same time. The presence of the interaction between 
miRNA and mRNA would reduce the firefly luciferase activity normalized to the Renilla luciferase 
activity of the control transfection. In the presence of miR-148a mimic, the constructs bearing the  
3' UTR of ACVR1 mRNA showed decreases in luciferase activity of 50% compared with the control 
(Figure 2). 
To further investigate whether the putative target site was regulated by miR-148a, we introduced 
point mutations to the corresponding seed sequence at pmirGLO-ACVR1-3'UTR to eliminate the 
predicted binding by miR-148a. As shown in Figure 2, suppression of the reporter activity by   
miR-148a was almost fully relieved by mutation of the conserved seed complementary site, denoting 
that the matching site identified strongly contribute to the miRNA:mRNA interaction that mediates the 
post-transcriptional inhibition of the ACVR1 expression. 
Figure 2. miR-148a directly targets human ACVR1 3' UTR. Relative luciferase activity 
derived from pmirGLO-ACVR1-3'UTR or pmirGLO-ACVR1-3'UTR-mut were   
co-transfected with miR-148a mimic or NC mimic in HeLa cells. The transfection of 
pmirGLO-ACVR1-3'UTR or pmirGLO-ACVR1-3'UTR-mut alone was used as control 
(Mock). Fireﬂy and Renilla luciferase activities were determined, and ﬁreﬂy luciferase was 
normalized to Renilla luciferase activity. Results are expressed as relative activities against 
the activity of mock mimic transfection. ** p < 0.01. 
 
2.2. Endogenous Target Post-Transcriptional Repression by miR-148a 
To investigate the effects of miR-148a on the endogenous expression of its targets and in order to 
obtain high miR-148a expression levels, we transiently transfected miR-148a mimic into HeLa cells, 
and a NC mimic was used as a control. After transfection (48 h or 72 h), the expression of miR-148a 
was tested by quantitative Real time PCR (qRT-PCR) and the mRNA or protein expression of ACVR1 
was determined by qRT-PCR or western blot analysis. Obviously, the expression of miR-148a was 
increasing dramatically compared with negative control samples (Figure 3A). In HeLa cell line, both 
mRNA and protein levels of ACVR1 were significantly reduced by miR-148a overexpression Int. J. Mol. Sci. 2012, 13                 
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compared with negative controls (Figure 3B–D). The results showed that enforced expression of   
miR-148a led to a significant decrease in endogenous ACVR1 mRNA and protein, suggesting that the 
endogenous expression of ACVR1 was down regulated by miR-148a. 
Figure 3. Verification of target genes of miR-148a. (A) QRT-PCR results of miR-148a 
expression level in HeLa cells transfected with miR-148a mimic or NC mimic for 48 h. 
RNU44 (RNA, U44 small nuclear) was used as the normalization control. (B) QRT-PCR 
results of mRNA level of ACVR1 in HeLa cells transfected as described in A. GAPDH 
was used as the normalization control. (C) Western blot analysis of ACVR1 protein level 
in HeLa cells transfected as described in A for 72 h. (D) The bands’ intensity in C is 
quantified using the ImageJ 1.43 software [42]. The relative intensity against β-actin  
was calculated, and fold change relative to the relative intensity in transfected NC cells  
is presented. 
 
2.3. Inhibition of BMP Signaling by miR-148a 
To investigate whether the inhibition of ACVR1 by miR-148a could influence the BMP signaling 
pathway, we examined the endogenous mRNA levels of Id1-4 when miR-148a was overexpressed in 
HeLa cells. QRT-PCR of transfected HeLa cells showed that miR-148a overexpression significantly 
decreased the mRNA expression of Id1, Id2 and Id3 in a dose-dependent way (Figure 4). In contrast, 
the expressions of Id4 mRNA had no significant difference between two groups. Id4 mRNA was 
detected at very low abundance with high ct values in qRT-PCR assay. Int. J. Mol. Sci. 2012, 13                 
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HeLa cells have previously been reported to have an indirect osteogenic effect by secreting BMP4 
and BMP6 continuously to the surrounding host cells when implanted in a mouse model of heterotopic 
bone formation [43–45]. HeLa cells have been shown to be strongly positive for alkaline phosphatase 
(ALP) activity, with high expressing levels of several ALP isoforms [46,47]. In addition, HeLa cells 
have been reported to deposit mineral in osteogenic medium treated cell cultures and express 
osteocalcin, which is an established osteogenic marker [47–49]. The osteogenic properties of HeLa cell 
line make it suitable for BMP signaling pathway research. Ids are key component of the BMP 
signaling pathway [13]. The mRNA and protein expression of Ids could be dectected in HeLa cells 
except Id4 [50,51]. The decreased mRNA expression of Id1–3 indicated that the BMP signaling was 
inhibited after miR-148a overexpression. 
Figure 4. miR-148a inhibition of the BMP signaling pathway detected as reduced 
expression of Id1–3 mRNA levels. The mRNA levels of Id1–4 were detected by qRT-PCR 
in HeLa cells transfected with 5, 10,or 20 pmol miR-148a mimic or NC mimic for 48 h.  
* p < 0.05, ** p < 0.01, 
ns p > 0.05. 
 
miRNAs are of ever increasing importance as post-transcriptional regulators of gene expression 
following transcription. They have been demonstrated to play a significant role in osteogenic 
differentiation by altering expression of important genes in different pathways [52–54]. In this study, 
we have confirmed by multiple methods that miR-148a regulated the expression of ACVR1 by directly 
targeting the 3' UTR of its mRNA, revealing a mechanism of post-transcriptional regulation of 
ACVR1 expression. 
ACVR1 is a very important protein in TGF-β and BMP pathway. The constitutively activating 
mutation (c.G617A, p.R206H) of ACVR1 dysregulates BMP signaling and initiates the formation of a 
second skeleton of heterotopic bone [2–6]. It is reported that ACVR1 is also very important in   
EndMT [15]. In our knowledge, there is still no effective inhibitor for ACVR1. miRNAs mediated  
post-transcription silence has been used in therapy [24,55]. We found miR-148a could directly regulate 
the expression of ACVR1 both at mRNA and protein level by binding to the complementary sites in 
the 3' UTR of ACVR1 mRNA. The mutations or single nucleotide polymorphisms in miRNA binding 
sites could influence normal miRNA mechanisms, which may cause diseases [56–58] or phenotypic Int. J. Mol. Sci. 2012, 13                 
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variation [59]. However, in this study we found the miR-148a binding sites were conserved in different 
vertebrates. So we speculate that miR-148a could be used to inhibit the constitutive activity mutated 
ACVR1 as it targets the 3' UTR of ACVR1 mRNA, regardless of the mutation in the translated region. 
In addition, as activated ACVR1 is very important for EndMT, miR-148a inhibitor may be useful to 
activate ACVR1 expression or enhance its expression. However, it should be noted that this study has 
been examined only in HeLa cells. Further researches were needed to further validate the effect of 
miR-148a on other types of cells especially endothelial cells. Despite its preliminary character, this 
study can clearly indicate that ACVR1 was a target of miR-148a, thus may provide a new approach for 
FOP therapy in the future. 
3. Experimental Section 
3.1. Cell Culture 
HeLa cells and A549 cell lines were cultured in RPMI medium 1640 supplemented with 10% fetal 
bovine serum, 100 units/mL penicillin and 100 units/mL streptomycin in a humidified chamber 
containing 5% CO2 at 37 °C. 
3.2. Plasmid Construction 
Genomic DNA was isolated from A549 cells using a Genomic DNA Purification kit (Promega, USA). 
A 1 kb fragment(+1~+1001, chromosome 2: 158,593,042–158,594,042) of 3' UTR (total 1102 bp) of 
human ACVR1 gene was amplified using Pfu polymerase and the following primer set was designed 
according to the reference sequence of human ACVR1 mRNA(NM_001111067): ACVR1-3'UTR-F: 
5'-CCTCGAGCATTTTCATAGTGTCAAGAAGGAAGA-3' (XhoI); ACVR1-3'UTR-R:   
5'-AGTCGACTCTGGCAGAGTTTAAATGCACGTAAT-3' (SalI). The obtained DNA fragment was 
inserted into the pmirGLO Vector (Promega, USA). The resulting vector was sequence-verified and 
named pmir-ACVR1-3'UTR. 
3.3. miRNA Targets Prediction  
In this study, TargetScan 5.1 [39], miRanda [40] and miRDB [41] were used for identification of 
miRNA target sites. 
3.4. Site-Directed Mutagenesis 
The vector pmir-ACVR1-3'UTR was utilized to perform site-directed mutagenesis of the putative 
miR-148a binding sites following the quick change site-directed mutagenesis protocol (Stratagene, 
USA). The mutant bases in putative miR-148a seed sequence were shown in Figure 1B. The 
oligonucleotides incorporating mutant bases were as follows: 5'-CAAGTTGGGTCTTTAAAA 
TTAAGAGTAAGACTCGAAGTAAGGAATGCAAAAATTCCTAGTG-3'.  The PCR reaction was 
performed for 30 cycles (95 °C for 30 s, 55 °C for 30 s, 68 °C for 10 min) following an initial 
denaturation at 95 °C for 30 s. The mixture of input and amplified DNA was digested directly with Int. J. Mol. Sci. 2012, 13                 
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DpnI and then transformed into XL-10 Blue cells. The nucleotide sequences of the mutant were 
confirmed by sequencing, and the resulting vector was named pmir-ACVR1-3'UTR-mut. 
3.5. miRNAs and Transfection 
The hsa-miR-148a (MI0000253) mimic and NC mimic (5'-UUCUCCGAACGUGUCACGUTT-3') 
were synthesized by GenePharma (Shanghai, China). The miRNA transfection was performed using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. In 
brief, cells were plated in 6-well plate to 40%–60% confluence. For each well, 100 pmol miR-148a 
mimic or NC was added. Total RNA or protein were prepared 48 h or 72 h after transfection and were 
used for qRT-PCR or western blot analysis. To study the potential effect of miR-148a on BMP 
signaling pathway, cells were plated in 24-well plates and transfected with 5, 10 or 20 pmol of   
miR-148a mimic or NC using Lipofectamine 2000. The cells were harvested at 48 h post-transfection 
for qRT-PCR analysis. 
3.6. RNA Isolation and Real-Time PCR Analysis 
Total RNA was isolated using the mirVana miRNA PARIS kit (Ambion), in accordance with the 
manufacture’s protocol. A total of 0.5 μg of RNA from each sample was used to generate cDNA by 
reverse transcription with the PrimeScript RT reagent Kit (Takara, Japan). Using the resulting cDNAs 
as templates, the gene expression levels were measured using an ABI Prism 7500 (Applied Biosystems, 
USA) and SYBR
® Premix Ex Taq™ II (Takara, Japan) according to the manufacturer’s instructions. 
GAPDH was used as reference for normalizing data. The primer sequences for measurement of mRNA 
expression were: 5'-TGGAGAAACCTGCCAAGTATG-3' (GAPDH-forward); 5'-GGAGACAACCT 
GGTCCTCAG-3' (GAPDH-reverse); 5'-GCAACCAAGAACGCCTCAATC-3' (ACVR1-forward);   
5'-TTTCCCGACACACTCCAACAG-3'(ACVR1-reverse). 5'-TACATCAGGGACCTTCAGTTGGAG-3' 
(Id1-forward); 5'-TTCAGCGACACAAGATGCGATC-3' (Id1-reverse); 5'-TGTGGCTGAATAA 
GCGGTGTTC-3' (Id2-forward); 5'-TCCATTCAACTTGTCCTCCTTGTG-3' (Id2-reverse);   
5'-CCCACCTTCCCATCCAGACAG-3' (Id3-forward); 5'-TGGGCAGGGCGAAGTTGG-3' (Id3-reverse); 
5'-AACAAGCAGGGCGACAGCATTC-3' (Id4-forward); 5'-GCTCCTGGCTCGGGCTCAG-3'   
(Id4-reverse). 
Quantitative RT-PCR of miRNAs was performed using Taqman MicroRNA assays (Applied 
Biosystems, USA) according to the manufacturer’s instructions with the 7500 real-time RT-PCR system. 
The expression level of the small nuclear RNU44 was used as the normalization control. All assays 
were performed in quadruplicate. The relative expression levels were calculated using the 2
−ΔΔCt method.  
3.7. Luciferase Reporter Assay 
HeLa cells were seeded in 48-well plate, grown to a density of 80%–90% confluence and then  
co-transfected to each well with 150 ng of luciferase reporter vector and 10 pmol miRNAmimic using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Cells 
were harvested and lysed in 50 μL of passive lysis buffer 24 h post-transfection. A fraction of protein 
was subjected to a dual-luciferase reporter assay system (Promega, USA). Firefly luciferase activity Int. J. Mol. Sci. 2012, 13                 
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and Renilla luciferase activity were measured sequentially by a Veritas Microplate Luminometer 
(Turner BioSystems, USA). Fireﬂy luciferase activity was normalized to Renilla luciferase activity. All 
transfections were performed in triplicate, and the luciferase activities were expressed as the mean ± SD 
of three independent experiments.  
3.8. Western Blot 
After transfection, the cells were collected and washed with cold PBS three times. The PBS was 
decanted, and the cell pellet was resuspended in 100 μL of lysis buffer (Fermentas, Canada) for 10 min 
on ice. The resulting solution was then combined with 25 μL 5× SDS sample buffer and boiled for  
10 min. The samples were resolved on a 10% SDS-PAGE gel and transferred to PVDF membranes 
(Millipore, USA). The membranes were blocked using 5% nonfat dry milk for 1 h at room temperature. 
The filters were incubated overnight with primary antibodies at 4 °C and then washed. After further 
incubation with a secondary antibody conjugated with HRP for 1 h at room temperature, the 
membranes were washed extensively, and the signals were developed by Immun-starHRP 
Chemiluminescent Kit (Bio-Rad, USA). Western blots were quantified using the ImageJ 1.43 software 
(National Institutes of Health, Bethesda, MD) after densitometric scanning of the films. Antibodies 
directed against ACVR1(sc-25449) and β-actin (sc-47778) were purchased from Santa Cruz 
Biotechnology (Santa Cruz, USA); goat anti-mouse(GAM)-HRP conjugate (# 170-5047) and goat   
anti-rabbit (GAR)-HRP conjugate (# 170-5046) were purchased from Bio-Rad. β-actin was used as a 
loading control. 
3.9. Statistical Analysis 
Data was expressed using the mean and the standard deviation when at least three independent 
experiments were performed. Statistical analysis was performed using the two-tailed student’s t-test, 
and p < 0.05 was considered of significant difference. 
4. Conclusions 
We demonstrated that miR-148a could regulate the expression of ACVR1 by directly targeting the 
3' UTR of its mRNA and modulate the BMP signaling pathway, which suggest that miR-148a could be 
used as a new target for the development of therapeutic agents against FOP. 
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